Stocks News

LAST PRICE
21.8100
TODAY'S CHANGE (%)
Trending Up0.2900 (1.3476%)

Bid / Lots
21.8500/ 1
Ask / Lots
22.1000/ 1
Open / Previous Close
21.5400 / 21.5200
Day Range
Low 21.3100
High 22.0200
52 Week Range
Low 13.1400
High 25.3400
Volume
907,058
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Nov 7, 2024
- DJ Syndax Pharmaceuticals Is Maintained at Buy by Goldman Sachs, from 12:02PM ET on Thursday Nov 07, 2024 by Dow Jones
  12:02PM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: SNDX
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/SNDX/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 07, 2024 12:02 ET (17:02 GMT)
Nov 6, 2024
- DJ Syndax Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co., from 7:12AM ET on Wednesday Nov 06, 2024 by Dow Jones
  7:12AM ET on Wednesday Nov 06, 2024 by Dow Jones
  Companies Mentioned: SNDX
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/SNDX/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 06, 2024 07:12 ET (12:12 GMT)
Nov 5, 2024
- -- Earnings Flash (SNDX) SYNDAX PHARMACEUTICALS Reports Q3 Revenue $12.5M, from 4:04PM ET on Tuesday Nov 05, 2024 by MT Newswires
  4:04PM ET on Tuesday Nov 05, 2024 by MT Newswires
  Companies Mentioned: SNDX
  04:04 PM EST, 11/05/2024 (MT Newswires) -- ...
- Syndax Reports Third Quarter 2024 Financial Results and Provides Business Update, from 4:01PM ET on Tuesday Nov 05, 2024 by PR Newswire
  4:01PM ET on Tuesday Nov 05, 2024 by PR Newswire
  Companies Mentioned: SNDX
  New revumenib and Niktimvo™clinical data will be highlighted at 66th ASH Annual Meeting -
  mNPM1 AML topline data from AUGMENT-101 expected in 4Q24; potential sNDA filing in 1H25 -
  Revumenib NDA in R/R KMT2Ar acute leukemia is being reviewed under RTOR; PDUFA action date of December 26, 2024 -
- *DJ Syndax Pharmaceuticals 3Q Loss $84.1M >SNDX, from 4:01PM ET on Tuesday Nov 05, 2024 by Dow Jones
  4:01PM ET on Tuesday Nov 05, 2024 by Dow Jones
  Companies Mentioned: SNDX

Nov 8, 2024
- Disc Medicine Gets $200 Million Loan From Hercules Capital, from 10:41AM ET on Friday Nov 08, 2024 by MT Newswires
  10:41AM ET on Friday Nov 08, 2024 by MT Newswires
  Companies Mentioned: HTGC, IRON
- Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc., from 8:30AM ET on Friday Nov 08, 2024 by Dow Jones
  8:30AM ET on Friday Nov 08, 2024 by Dow Jones
  Companies Mentioned: HTGC, IRON
- Press Release: Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc., from 8:30AM ET on Friday Nov 08, 2024 by Dow Jones
  8:30AM ET on Friday Nov 08, 2024 by Dow Jones
  Companies Mentioned: HTGC, IRON
Nov 7, 2024
- Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update, from 4:05PM ET on Thursday Nov 07, 2024 by PR Newswire
  4:05PM ET on Thursday Nov 07, 2024 by PR Newswire
  Companies Mentioned: SYRE
- Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update, from 4:05PM ET on Thursday Nov 07, 2024 by Dow Jones
  4:05PM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: SYRE
- Press Release: Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update, from 4:05PM ET on Thursday Nov 07, 2024 by Dow Jones
  4:05PM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: SYRE
Nov 6, 2024
- Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024, from 4:30PM ET on Wednesday Nov 06, 2024 by Dow Jones
  4:30PM ET on Wednesday Nov 06, 2024 by Dow Jones
  Companies Mentioned: TARS
Nov 5, 2024
- DJ Disc Medicine Is Maintained at Sector Outperform by Scotiabank, from 6:59PM ET on Tuesday Nov 05, 2024 by Dow Jones
  6:59PM ET on Tuesday Nov 05, 2024 by Dow Jones
  Companies Mentioned: IRON
- Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 4:01PM ET on Tuesday Nov 05, 2024 by Dow Jones
  4:01PM ET on Tuesday Nov 05, 2024 by Dow Jones
  Companies Mentioned: VRDN
- DJ Disc Medicine Price Target Maintained With a $70.00/Share by HC Wainwright & Co., from 9:45AM ET on Tuesday Nov 05, 2024 by Dow Jones
  9:45AM ET on Tuesday Nov 05, 2024 by Dow Jones
  Companies Mentioned: IRON

Syndax Pharmaceuticals Inc
NASDAQ:SNDXUnited States

Search Criteria

Nov 7, 2024

DJ Syndax Pharmaceuticals Is Maintained at Buy by Goldman Sachs, from 12:02PM ET on Thursday Nov 07, 2024 by Dow Jones

Nov 6, 2024

DJ Syndax Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co., from 7:12AM ET on Wednesday Nov 06, 2024 by Dow Jones

Nov 5, 2024

-- Earnings Flash (SNDX) SYNDAX PHARMACEUTICALS Reports Q3 Revenue $12.5M, from 4:04PM ET on Tuesday Nov 05, 2024 by MT Newswires

Syndax Reports Third Quarter 2024 Financial Results and Provides Business Update, from 4:01PM ET on Tuesday Nov 05, 2024 by PR Newswire

*DJ Syndax Pharmaceuticals 3Q Loss $84.1M >SNDX, from 4:01PM ET on Tuesday Nov 05, 2024 by Dow Jones

Peers Headlines

Nov 8, 2024

Disc Medicine Gets $200 Million Loan From Hercules Capital, from 10:41AM ET on Friday Nov 08, 2024 by MT Newswires

Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc., from 8:30AM ET on Friday Nov 08, 2024 by Dow Jones

Press Release: Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc., from 8:30AM ET on Friday Nov 08, 2024 by Dow Jones

Nov 7, 2024

Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update, from 4:05PM ET on Thursday Nov 07, 2024 by PR Newswire

Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update, from 4:05PM ET on Thursday Nov 07, 2024 by Dow Jones

Press Release: Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update, from 4:05PM ET on Thursday Nov 07, 2024 by Dow Jones

Nov 6, 2024

Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024, from 4:30PM ET on Wednesday Nov 06, 2024 by Dow Jones

Nov 5, 2024

DJ Disc Medicine Is Maintained at Sector Outperform by Scotiabank, from 6:59PM ET on Tuesday Nov 05, 2024 by Dow Jones

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 4:01PM ET on Tuesday Nov 05, 2024 by Dow Jones

DJ Disc Medicine Price Target Maintained With a $70.00/Share by HC Wainwright & Co., from 9:45AM ET on Tuesday Nov 05, 2024 by Dow Jones